New treatments for fatty liver disease linked to obesity
Novel IP6K1 inhibitors for treatment of NAFLD/NASH
This study is looking at how a certain enzyme called IP6K1 affects liver problems like non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, especially in people who are overweight, and it hopes to find new treatments that can help reduce liver fat and improve overall health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11057579 on NIH RePORTER |
What this research studies
This research investigates the role of a specific enzyme, IP6K1, in the development of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), conditions often associated with obesity. The study aims to develop novel inhibitors that can target IP6K1, potentially reducing liver fat accumulation and improving metabolic health. By understanding how this enzyme affects insulin resistance and liver inflammation, the research seeks to identify new therapeutic strategies for patients suffering from these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with NAFLD or NASH, particularly those who are also experiencing obesity-related health issues.
Not a fit: Patients without obesity or those who do not have NAFLD or NASH may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for patients with fatty liver disease, improving their liver health and overall metabolic function.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways related to obesity and liver disease, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Wang, Xiaodong — Univ of North Carolina Chapel Hill
- Study coordinator: Wang, Xiaodong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.